The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.


Journal

Cellular immunology
ISSN: 1090-2163
Titre abrégé: Cell Immunol
Pays: Netherlands
ID NLM: 1246405

Informations de publication

Date de publication:
09 2019
Historique:
received: 15 09 2017
revised: 22 10 2017
accepted: 26 10 2017
pubmed: 10 11 2017
medline: 12 5 2020
entrez: 10 11 2017
Statut: ppublish

Résumé

Osteosarcoma is a rare primary bone cancer characterized by cancer cells producing calcified osteoid extracellular matrix and inducing lung metastases with a high frequency. The local microenvironment defined several tumor niches controlling the tumor growth and cell extravasation. The immune infiltrate composes one of these niches. The immune environment of osteosarcoma is mainly composed by T-lymphocytes and macrophages but also contains other subpopulations including B-lymphocytes and mast cells. Osteosarcoma cells control the recruitment and differentiation of immune infiltrating cells and establish a local immune tolerant environment favorable to the tumor growth, drug resistance and the occurrence of metastases. Osteosarcoma cells are able to affect the balance between M1 and M2 macrophage subtypes and so could control the T-lymphocyte responses via the PD-1/PDL-1 system. In addition, mesenchymal stem cells may also contribute to this immune tolerance and strengthen the immune evasion. The present review gives a brief overview of the immune components of osteosarcoma and their most recent therapeutic interests.

Identifiants

pubmed: 29117898
pii: S0008-8749(17)30189-2
doi: 10.1016/j.cellimm.2017.10.011
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103711

Informations de copyright

Copyright © 2017. Published by Elsevier Inc.

Auteurs

Marie-Françoise Heymann (MF)

Institut de Cancérologie de l'Ouest, site René Gauducheau, INSERM, UMR1232, Boulevard Professeur Jacques Monod, 44805 Saint-Herblain, France; University of Sheffield, Department of Oncology and Metabolism, INSERM, European Associated Laboratory "Sarcoma Research Unit", Medical School, Beech Hill Road, S10 2RX, Sheffield, UK.

Frédéric Lézot (F)

INSERM, UMR1238 Team1, Faculty of Medicine, Nantes, France; University of Nantes, Faculty of Medicine, 44035 Nantes, France.

Dominique Heymann (D)

Institut de Cancérologie de l'Ouest, site René Gauducheau, INSERM, UMR1232, Boulevard Professeur Jacques Monod, 44805 Saint-Herblain, France; University of Sheffield, Department of Oncology and Metabolism, INSERM, European Associated Laboratory "Sarcoma Research Unit", Medical School, Beech Hill Road, S10 2RX, Sheffield, UK; University of Nantes, Faculty of Medicine, 44035 Nantes, France. Electronic address: dominique.heymann@univ-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH